Last reviewed · How we verify
NCT06293261
Multicenter, Prospective, Non-interventional, Observational Study to Confirm the Long-term Efficacy and Safety of Rosuampin Tab. in Patients With Hypertension and Hypercholesterolemia
trial testing Rosuampin 5/5mg, 10/5mg, 20/5mg, 10/10mg in Hypertension in 5,047 participants. Completed in 31 March 2024.
31 March 2024
Quick facts
| Lead sponsor | Yuhan Corporation |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 5,047 |
| Start date | 27 June 2020 |
| Primary completion | 31 March 2024 |
| Estimated completion | 31 March 2024 |
| Sites | 39 locations across South Korea |
Drugs / interventions tested
- Rosuampin 5/5mg, 10/5mg, 20/5mg, 10/10mg — full drug profile →
Conditions studied
- Hypertension — all drugs for Hypertension →
- Hypercholesterolemia — all drugs for Hypercholesterolemia →
Sponsor
Yuhan Corporation — full company profile →
Who can join
19 and older, any sex, with Hypertension or Hypercholesterolemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is to confirm the long-term efficacy and safety of Rosuampin Tab. in patients with hypertension and hypercholesterolemia
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06293261
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hypertension
Currently open trials in the same condition.
- NCT07413159 — The "Check, Monitor, Control Hypertension" Study is a 24-month Randomized Trial in Houston Targeting African Americans A · NA · recruiting
- NCT07361276 — Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care S · recruiting
- NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
- NCT07238400 — Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia · Phase 2 · recruiting
- NCT07135505 — Early Time-Restricted Eating in Older Adults With Hypertension · NA · recruiting
Other Yuhan Corporation trials
Trials by the same sponsor.
- NCT07470125 — Bioequivalence (BE) Study Between YHP2511 and YHP2511A in Healthy Volunteers · Phase 1 · not yet recruiting
- NCT07415551 — Phase 2 Study of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1- · Phase 2 · recruiting
- NCT07265167 — Bioequivalence Study Between YHP2406 and YHR2501 in Healthy Subjects · Phase 1 · completed
- NCT07111468 — Clinical Trial to Evaluate the Efficacy and Safety of YHP2401 Compared to YHR2402 and YHR2403 for Acute Bronchitis · Phase 3 · completed
- NCT06920719 — Bioequivalence Study betweenYHP2406 and YHR2501 in Healthy Subjects · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06293261 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yuhan Corporation
- Last refreshed: 22 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06293261.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing